Checkpoint Combo Runs the Table in Early CRC

]]>(MedPage Today) -- Neoadjuvant therapy with nivolumab (Opdivo) and ipilimumab (Yervoy) led to pathologic responses in 100% of a small cohort of patients with mismatch repair-deficient (dMMR) colorectal cancer (CRC) and a fourth of MMR-proficient...